Home
1 888 2 DONATE(1 888 236-6283)
CLINICSDONORSVOLUNTEERSHOSPITALSMEDIA ROOMABOUT USCAREERS
Find a Clinic:  search Search this site:  search
Book an appointment
Home > Hospitals >
Facebook youTube Twitter flickr
Why Should I Donate?
Who Needs Blood?
Can I donate?
Basic Eligibility
Donor Questionnaire
Malaria policy
Donation Date Calculator
American Sign Language
MSM
What Can I Donate?
Types of Donations
Blood
Plasma & Platelets
Stem Cells
Financial Gifts
Blood for Research
How Can I Get Involved?
In My Community
Send an e-card
Public Involvement
Volunteers
Partners for Life
What's Your Type
Sign Up to Learn More
OneMatch
Young Blood For Life
Assignment Saving Lives
National Blood Donor Week
What Should I Know?
FAQs
Pandemic Preparedness
Safety and Testing
Research & Development
West Nile Virus (WNV)
Transfusion Related Acute Lung Injury (TRALI)
vCJD Travel Deferral
Blackboard
Forms
Become a Volunteer
New Donor Form
Change Your Address
Join OneMatch
Become a Partner for Life Organization
Become a Partner for Life Member
Join Ready, Set... Give!
Donor Experience Survey
Hospitals
Customer Service
Circular of Information
Customer Letters
Plasma Protein Products
TransfusionMedicine.ca
Hospital Customer Forms
Resource Library
OneMatch Documents
Adverse Events
Diagnostic Services
 

Customer Letter Archive

Please note, the following Customer Letters, in electronic format, do not replace the print version that you receive from your local Canadian Blood Services site. The print version must be retained as your file copy.

Protect yourself! Download the latest version of Adobe Reader before you view or download PDFs online.

Download Adobe Reader free >>



2014 | 2013 | 2012 | 2011 |2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

2013

Letter # Date Title
2013-31 2013-12-19 Information Only
Availability of Gammagard Liquid Immune Globulin Intravenous (Human), [IGIV] 10%

2013-30 2013-12-12 Information Only
(not applicable for hospitals in the provinces of British Columbia and Manitoba)

Hospital Disposition Improvement Initiative – Changes to the Hospital Blood Component Report

Web-Based Disposition System Data Entry Field Definitions



2013-29 2013-12-03 Information Only
PROGESA Blood Management Software Upgrade

Attachment 1 of 2

Attachment 2 of 2



2013-28 2013-11-12 Information Only
Changes to Plasma Protein Products Distributed by Canadian Blood Services

Canadian Blood Services Hizentra 50mL DCL

Dear clinician ATIII

Temp Change Notice



2013-27 2013-11-07 Information Only
Expiry Date of ADVATE 3000 IU Kit Lot# LE01N535AE

Expiry Date of ADVATE 3000 IU Kit Lot# LE01N535AE letter



2013-26 2013-10-09 Manitoba Only
RESCIND NOTIFICATION
Changes to the Facility Return Process



2013-26 2013-10-01 RESCIND NOTIFICATION
Changes to the Facility Return Process



2013-25 2013-09-16 Important Information
Confirmed Implementation Date and Consolidation of Washed Red Blood Cell Sites with Implementation of Extended Expiry



2013-24 2013-08-29 INFORMATION ONLY
Delay in Launch of CINRYZE™,(C1 inhibitor [human])

Supplier Letter ViroPharma re: Cinryze

2013-23 2013-08-14 INFORMATION ONLY
Babesiosis and Hepatitis E Seroprevalence Study

2013-22 2013-07-22 IMPORTANT INFORMATION
Washed Red Blood Cell with Extended Expiry Implementation

Attachment 1 Washed Red Cell Product Bag with Blank Label

Attachment 2 Washed Red Cell Label with SAGM Added

Attachment 3 Information Tag with Accurate Volume

Attachment 4 Information Tag Indicating Extra Wash

Attachment 5 Information Tag with Accurate Volume and Extra Wash

Attachment 6 Special Request Order Form

Attachment 7 Formulaire de commande spéciale (Culot Globulaire)

2013-21 2013-07-18 IMPORTANT INFORMATION
Launch of CINRYZE™,(C1 inhibitor [human])

New therapeutic option for prevention of hereditary angioedema (HAE) attacks now available through Canadian Blood Services

2013-20 2013-07-11 IMPORTANT INFORMATION
Privigen® 40g vial size available for distribution in Canada

Privigen® 40g vial size available for distribution in Canada

2013-19 2013-06-13 IMPORTANT INFORMATION
Requisition For Blood Group Genotyping (Patient) NIRL/
Requisition For Antibody Investigation NIRL

Requisition for Blood Group Genotyping (Patient)
National Immunohematology Reference Laboratory (NIRL)


REQUISITION FOR ANTIBODY INVESTIGATION
National Immunohematology Reference Laboratory (NIRL)


2013-18 2013-05-27 Information Only
New Contact Information for all Atlantic Medical Offices at Canadian Blood Services

2013-17 2013-05-15 Information Only
Change to Canadian Blood Services Tamper Indicator Device - All Hospitals EXCEPT BC & Yukon Hospitals

2013-16 2013-05-08 Information Only
Changes to Plasma Protein Products Distributed by Canadian Blood Services

New pre-filled diluent Syringe with Kogenate® FS

Privigen® 2.5g vial size available for distribution in Canada

What's New With BeneFIX®? New Indication. New Vial Size.

Addition of Ancillaries to Berinert® Package

2013-15 Update 2013-05-16 Information Only
Circular of Information – Release of the Red Blood Cells LR SAGM Added

Updates to the Frozen & Deglycerolized Red Blood Cell Processes at Canadian Blood Services,

April 2013 Version

2013-15 2013-05-02 Information Only
Circular of Information – Release of the Red Blood Cells LR SAGM Added

Updates to the Frozen & Deglycerolized Red Blood Cell Processes at Canadian Blood Services

April 2013 Version

2013-14 2013-05-01 Information Only
Canadian Blood Services Logistics Delivery Pilot - Dartmouth Production and Distribution Site

2013-13 2013-04-24 Information Only
Washed Red Blood Cells With Extended Expiry ISBT 128 Sample Labels and Product Codes

Attachments

Product Codes and Label Text

WASH RBC LR SAGM 2-1

WASH RBC LR SAGM 2-2

WASH RBC LR SAGM 2-3

WASH RBC LR SAGM 2-4

2013-12 2013-04-22 Information Only
Launch of octagam® 10% Immune Globulin Intravenous (Human)

Octagam Canadian Blood Services HCP introduction letter

Canadian Blood Services Octagam product profile letter

2013-11 2013-04-11 Information Only
RiaSTAP and Haemocomplettan® P Distribution

2013-10 Update II 2013-06-06 Information Only
Phenotype Tag L040995

2013-10 Update 2013-05-09 Information Only
Phenotype Tag L040995

2013-10 2013-04-08 Information Only
Improvements to Donor Red Cell Phenotype Tags

Phenotype Information Provided to Hospitals by Canadian Blood Services Red Blood Cell Label and Tags

2013-09 2013-03-18 Information Only
2012 Hospital Satisfaction Survey Summary

2013-08 2013-03-11 Information Only
Important Information Regarding Availability of Immune Globulin Products and Prothrombin Complex Concentrates for 2013-2014

2013-07 2013-02-13 Information Only
Product Labeling Change for Deglycerolized Red Blood Cells including Circular of Information Change and Labeling Change for Frozen Red Blood Cells

Attachment #1

Attachment #2

2013-06 2013-02-12 Information Only
Tretten® Distribution

INTRODUCING TRETTEN®: A RECOMBINANT COAGULATION FXIII-A21*

Tretten® (catridecacog) – A recombinant factor XIII A-subunit1

2013-05 2013-02-11 Action Required
Canadian Blood Services’ Saint John Site Move to Dartmouth Facility

2013-04 2013-01-22 Information Only
RiaSTAP Distribution

RiaSTAPTM (Fibrinogen Concentrate (Human), FCH)

2013-03 2013-02-07 Information Only
Emergency Framework - Synopsis for Triage Teams


2013-02 2013-01-21 Information Only
Recombinant Factor VIII Transition

2013-01 2013-01-07 Action Required
Canadian Blood Services’ Halifax Site Move to Dartmouth Facility

2012


Letter #

Date

Title

2012-35

2012-12-20

Change to the Canadian Blood Services Tamper Indicator Device - BC & Yukon Hospitals Only


2012-34

2012-12-05

Information Only
Release of the Circulars of Information October 2012 Version


2012-33

2012-10-04

Information Only
Plasma Protein Products Packing Slip Reduction


2012-32

2012-08-07

Requisition for Blood Group Genotyping (Patient)
Requisition for Antibody Investigation

Requisition for Blood Group Genotyping (Patient)

Requisition for Antibody investigation


2012-31

2012-07-30

INFORMATION ONLY
Important Information Regarding the Introduction of Octaplasma™
(Solvent Detergent (S/D)Treated Human Plasma)


2012-30

2012-07-19

INFORMATION ONLY
Factor VII Critical Supply Update

RE: Factor VII Critical Supply Update


2012-29

2012-07-16

INFORMATION ONLY
Notification on GAMMAGARD LIQUID 30g Lot LE12M055AB

RE: Notification on GAMMAGARD LIQUID 30g Lot LE12M055AB


2012-28

2012-06-28

INFORMATION ONLY
Changes to the Special Request Order Form and the Blood Component Order Form

Blood Component Order Form

Special Request Order Form (RBC)


2012-27

2012-06-27

INFORMATION ONLY
Factor VII Critical Supply Notice

RE: Factor VII Critical Supply Notice


2012-25

2012-06-14

INFORMATION ONLY
Health Canada Endorsed Important Safety Information on HepaGam B® (Hepatitis B Immune Globulin {Human} Injection)

NOTICE TO HOSPITALS Health Canada Endorsed Important Safety Information on HepaGam B® (Hepatitis B Immune Globulin [Human] Injection)


2012-24

2012-06-05

INFORMATION ONLY
Canadian Blood Services’ London Site Move to Brampton Facility


2012-23

2012-06-04

INFORMATION ONLY
Alburex®, Albumin (Human)
Changes to Temperature Storage

Alburex DCL storage


2012-22

2012-05-30

Information Only
Health Canada Endorsed Important Safety Information on Privigen®, Immune Globulin Intravenous (Human)

Health Canada Endorsed Important Safety Information on Privigen®, Immune Globulin Intravenous (Human)


2012-21

2012-05-24

INFORMATION ONLY
Xyntha® Solofuse™
Introducing SOLOFUSE™, a new all-in-one delivery device for XYNTHA®


2012-17 Correction

2012-05-23

CORRECTION
INFORMATION ONLY
Important Information Regarding the Introduction of Octaplasma™
(Solvent Detergent (S/D)Treated Human Plasma)


2012-20

2012-05-17

Discontinuation of Routine Platelet Yield Testing of Apheresis Platelets

Notification of Apheresis Platelet Yield


2012-19

2012-05-16

Circular of Information – Quality Control (QC) Criteria for Red Blood Cells LR SAGM added


2012-18

2012-05-14

Corporate Name Change for Wyeth & Extended Temperature Storage for BeneFIX® Coagulation Factor IX (Recombinant)

SJ Canadian Blood Services Letter BenXYN

Introducing the convenience of extended room temperature storage for BeneFIX


2012-17

2012-05-01

Important Information Regarding the Introduction of Octaplasma™
(Solvent Detergent (S/D)Treated Human Plasma)

Important treatment advance in Transfusion Medicine – Octaplasma® is now available in Canada

Attachment #1 - Solvent Detergent Plasma Request Form

Attachment #2 - Hospital Solvent Detergent Plasma Disposition Report

Attachment #3 - Octaplasma Labeling First 6 Lots

Attachment #4 - Octaplasma Labeling Future Labels


2012-16

2012-05-01

Change to the Shell of the Canadian Blood Services Shipping Containers


2012-15

2012-04-30

Revised dates for moves of Hamilton and London sites to Brampton

2012-14

2012-04-18

Update to the Phenotype Labelling Bug on the Red Blood Cell Component


2012-13

2012-04-12

Recommendations for the Notification of Recipients of a Blood Component Recall


2012-12

2012-04-03

Important Information Regarding Availability of Immune Globulin Products for 2012-2013


2012-11

2012-03-12

Canadian Blood Services’ Hamilton Site Move to Brampton Facility


2012-10

2012-03-08

Changes to Plasma Protein Products Distributed by Canadian Blood Services

COAGULATION FACTOR Comparison Table

Important treatment advance in von Willebrand disease (VWD) care - wilate® is now approved in Canada for VWD patients.

New Enhanced Reconstitution device for GAMMAGARD S/D

wilate®, now available in convenient 500 IU and 1000 IU vials of both FVIII and VWF per vial

ADVATE 2mL SWFI for 250IU and 500IU approved for distribution in Canada


2012-09

2012-03-07

IMPORTANT INFORMATION REGARDING PATIENT IgA/Anti-IgA TESTING REQUESTS

PATIENT REQUEST FOR IgA/ANTI-IgA TESTING FORM


2012-08

2012-02-29

Recommendations for Use of Prothrombin Complex Concentrates


2012-07

2012-02-27

2011 Hospital Satisfaction Survey Summary


2012-06

2012-02-21

Expanded Use of the Consignee (Customer) Notification Form


2012-02 Correction

2012-01-30

CORRECTION
INFORMATION ONLY
Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human)


2012-05

2012-01-26

Shipping Containers Utilized for RBC Shipments


2012-04

2012-01-25

Corporate Name Change for Talecris Biotherpeutics, Ltd & Redesigned Latex-free Stopper

Grifols product stopper redesign to address complaints related to latex-free stoppers used in 100, 50 and 25 mL formats

Canadian Blood Services Name Change Letter


2012-03

2012-01-23

Change in Distribution of Starches Part II


2012-02

2012-01-19

Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human)

Hizentra, 20%, Subcutaneous Immune Globulin (human), 20% solution for injection


2012-01

2012-01-09

Research Use of Blood Components

2011


Letter #

Date

Title

2011-37

2011-12-02

Donor Red Cell Phenotyping Labelling

2011-36

2011-11-29

New Process for Issuing and Labelling of Deglycerolized RBC’s with Incomplete Testing/Donor Assessment

2011-35

2011-11-28

Canadian Blood Services’ Toronto Site Move to Brampton Facility

2011-34

2011-11-21

IVIG-Associated Hemolysis

2011-33

2011-11-15

Revised Process for Emergency Release of Blood Components

2011-32

2011-10-20

FEIBA NF (Anti-Inhibitor Coagulant Complex, Vapor Heated, Nanofiltered) EXPANDED TEMPERATURE STORAGE of 2°C to 25°C

FEIBA NF 1000U and 2500U formats now approved with expanded temperature storage of +2°C to +25°C


2011-31

2011-10-12

Discontinuation of the CP2D Plasma Circular of Information

2011-30

2011-09-26

Changes to Canadian Blood Services Operations Medical On-Call Schedule Starting Week of October 3, 2011

2011-29

2011-09-20

Changes to Plasma Protein Products Distributed by Canadian Blood Services

IMPORTANT INFORMATION – 12 MONTHS ROOM TEMPERATURE STORAGE

Introduction of the “Next Generation” Mix2VialTM into octaplex® Product Kits


2011-28

2011-09-19

Canadian Guidelines for the Uniform Labelling of Blood and Blood Components Using ISBT 128

2011-27

2011-09-12

Changes to Physician’s Request for Directed Donation and Directed Donation Utilization Forms
Directed Donation Utilization Report

Physician's Request for Directed Donation

2011-26

2011-08-25

WinRho® SDF Product Information
Cangene Letter

2011-25

2011-08-25

Implementation of New Label Material

2011-24

2011-08-25

Updates to the Clinical Guide to Transfusion, New On-line Edition

2011-23

2011-08-16

Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD

2011-22

2011-08-15

Release of Plasma Component Circulars of Information – Change in Storage of Thawed Plasma from 24 Hours to 120 Hours (5 Days)

2011-21

2011-08-08

2011 Hospital Satisfaction Survey Summary

2011-20

2011-08-02

Availability of Beriplex® P/N (Human prothrombin complex)
Comparison Table
Behring letter

2011-19

2011-07-18

Donor Red Cell Phenotyping

2011-18

2011-07-14

Discontinuation of Printing Platelet Yields on Apheresis Platelet Labels

2011-17

2011-06-30

Important Information Regarding Phenotype Labelling Bug
Attachment

2011-16

2011-06-30

Important Information Regarding - Extended ISBT 128 Label
Attachment

2011-15

2011-06-28

Change in Distribution of Starches

2011-14

2011-06-27

Washed Red Blood Cells With Extended Expiry, Implementation Delay

2010-23
Correction

2011-06--27

CORRECTION - Expiration Time for Thawed Plasma (24 Hours vs. 5 Days)

2011-12
Correction

2011-06-13

CORRECTION - Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD

2011-13

2011-06-01

Talecris Stopper Redesign Project
Talecris Letter

2011-12

2011-05-17

Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD

2011-11

2011-05-03

New Label Material

2011-10

2011-04-14

Health Canada Endorsed Important Safety Information on Vivaglobin®
Behring letter

2011-09

2011-04-14

Donor Testing Announcement - Transfer of Donor Testing from Halifax to Toronto
(Distributed to Atlantic Canada Facilities only)

2011-08

2011-03-14

Change to Move Dates to the New Brampton Facility

2011-07

2011-03-09

Important Information Regarding Availability of Immune Globulin Products for 2011-2012

2011-06

2011-03-03

Release of the Circulars of Information February 2011 Version

2011-05

2011-02-28

FEIBA NF (Anti-Inhibitor Coagulant Complex, Vapor Heated and Nanofiltered) Replaces FEIBA VH
Baxter letter

2011-04

2011-02-22

CBS to Begin Labelling IgA Deficient SAGM Red Blood Cell Components

2011-03

2011-02-14

Introduction of MPX Testing (including HBV DNA)

2011-02

2011-01-31

Canadian Blood Services Evaluation of Current Use of Shipping Containers – Further Information

2011-01

2011-01-17

New Site Codes for Brampton and Dartmouth Facilities

/\ Top

2010


Letter #

Date

Title

2010-43

2010-12-07

Gamunex® and IGIVnex® (Immune Globulin Intravenous [Human], 10%) Now Indicated for Subcutaneous (SC) Administration
Attachment

2010-42

2010-12-01

F040275, Requisition for Antibody Investigation
Attachment

2010-40

2010-11-30

Labels on Plasma Components

2010-41

2010-11-29

Maritime Facilities Redevelopment Project-Logistics Test Plan Information for New Brunswick Hospitals

2010-39

2010-11-10

Canadian Blood Services Evaluating Current Use of Shipping Containers

2010-38

2010-11-03

New Consignee Notification Form For Confirmatory / Supplementary Test Results
Attachment

2010-37

2010-10-18

Hospital Satisfaction Survey Summary
Attachment

2010-36

2010-10-12

Licensed Berinert® & Mix2Vial™Transfer Device
Behring Letter Jul. 19, 2010
Behring Letter Oct. 7, 2010

2010-35

2010-10-12

Production Trial of New Label Material

2010-34

2010-09-27

NiaStase RT® Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable Now Available
Attachment

2010-33

2010-09-23

Gammagard Liquid: New Vial Size
Attachment

2010-32

2010-09-22

Circular of Information for AS-3 RBC and CP2D Platelet Components

2010-31

2010-09-20

Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan Further Information

2010-30

2010-09-09

Further Information to Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan

2010-29

2010-08-19

Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan UPDATE

2010-28

2010-08-10

Additional TRALI Reduction Measures for Plasma

2010-27

2010-07-28

Minor Modification to RBC Storage Container – Edmonton Site

2010-26

2010-07-27

Chagas Disease Lookback
Attachement

2010-25

2010-07-19

WinRho SDF Product Information
Cangene Letter

2010-24

2010-07-14

Important Information Regarding Updates to End Label for Double Components and New Héma-Québec Product Codes
Attachment 1
Attachment 2
Attachment 3

2010-23

2010-07-12

Expiration Time for Thawed Plasma (24 Hours vs. 5 Days)

2010-22

2010-07-05

Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan

2010-21

2010-06-29

Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan
Procedure for Spiking New Buffy Coat Blood Bags

2010-20

2010-06-28

Stability of Helixate® FS for Continuous Infusion
Behring letter

2010-19

2010-06-09

CSL Behring’s Privigen® Shelf Life Extension
Behring letter

2010-18

2010-06-09

NiaStase RT® Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable is coming to Canada
NiaStase letter

2010-17

2010-05-31

Packed Red Blood Cell Units from donors with Red Blood Cell Antibodies

2010-16

2010-05-27

Approved Use of BAXJECT II Hi-Flow Reconstitution Device with FEIBATM VH IMMUNO
Baxter letter

2010-15

2010-05-18

Introducing a new choice for patients….the Kogenate® FS 3000 IU vial
Bayer Letter

2010-14

2010-05-06

Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan

2010-13

2010-05-03

Circular of Information – CBS to Begin Selective Testing for Trypanosoma cruzi (T. cruzi) or Chagas Disease

2010-12

2010-04-14

Important Information Regarding Availability of Immune Globulin Products for 2010-2011

2010-11

2010-04-14

Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – Winnipeg

2010-10

2010-04-13

Humate-P® Made from Canadian Plasma and New Surgery Indication
Behring Letter
FVIII/vWF Products Comparison Table

2010-09

2010-03-29

Further Information Regarding Primary TRALI Reduction Measures

2010-08

2010-03-29

Association of WinRho® SDF ((Rho (D) Immune Globulin (Human)) with Intravascular Hemolysis in the Treatment of Immune Thrombocytopenic Purpura (ITP) – Important New Prescribing Information
Cangene letter

2010-07

2010-03-08

Further Implementation of Fenwal Blood Storage Bags at Canadian Blood Services – Hamilton

2010-06

2010-02-23

Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – Toronto

2010-05

2010-02-11

Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services

2010-04

2010-02-08

HepaGam B®
Cangene letter
HepaGam B regulatory status update
HBIg comparison table

2010-03

2010-01-28

Changes to Plasma Protein Products Distributed by Canadian Blood Services
Reconstitution of Octaplex
Behring letter

2010-02

2010-01-18

Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – North Eastern Ontario and Nunavut

2010-01

2010-01-18

Compatibility of Talecris Latex-Free 20 mm Stoppers with Various Spiking Devices
Compatibility of Talecris latex-free 20 mm stoppers with various spiking devices

/\ Top

2009


Letter #

Date

Title

2009-29

2009-12-22

dvate® 3000 IU approved for distribution in Canada
Baxter letter

2009-28

2009-12-08

Product Announcement: Xyntha™

2009-27

2009-12-01

Release of the Circulars of Information January 2009 Edition

2009-26

2009-12-07

Important Information Regarding ISBT 128 Donation Number Labels

2009-25

2009-10-26

Changes to Plasma Protein Products Distributed by Canadian Blood Services
Cytogam® Shelf Life Extension
CSL Behring's Haemocomplettan® P-Fibrinogen Concentrate

2009-24

2009-10-21

New TRALI Patient Data Form

2009-23

2009-10-19

Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services

2009-22

2009-10-08

Privigen® Increased Infusion Speed
Immune Globulin Comparison Table

2009-21

2009-10-05

Inventory Status Update and Pandemic Readiness

2009-20

2009-09-28

Minor Modification to RBC Storage Container

2009-19

2009-09-22

Important Information regarding the “Produced On” Date on CPD Platelets, Pooled, LR for Components

2009-18

2009-08-27

New sizes of frozen plasma storage cartons.

2009-12

2009-08-20

Important information regarding the 2004 Circular of Information

2009-17

2009-07-16

Changes to Plasma Protein Products Distributed by Canadian Blood Services
Baxter letter

New 2000 IU vial size and NIPRO Safe Touch PSV 25 gauge butterfly for Helixate® FS

Vivaglobin® Immune Globulin Subcutaneous is now available in 3ml vials

2009-15

2009-06-18

Important Information Regarding ISBT 128 Implementation

2009-16

2009-06-17

Important Information Regarding Availability of Immune Globulin Products for 2009-2010

2009-07

2009-06-17

Important Information Regarding TRALI Reduction Measures

2009-09

2009-06-08

Important Information Regarding New Héma Québec Product Codes

2009-01

2009-05-25

Important Information Regarding Circulars of Information

2009-14

2009-05-19

Changes to Plasma Protein Products Distributed by Canadian Blood Services
Octaplex letter
Wyeth letter

2009-13

2009-05-14

Important Information Regarding ISBT128 Implementation

2009-11

2009-05-11

Information Regarding the Availability of the Visual Assessment Guide

2009-10

2009-03-31

Incompatibility of Talecris Latex-free Stoppers and FluVen Infusion Sets.
Talecris letter

2009-08

2009-03-26

Important Information Regarding ISBT 128 Implementation
Attachment

2009-06

2009-03-02

Changes to Plasma Protein Products Distributed by Canadian Blood Services.
Gamunex IGIV/nex approved by Health Canada for CIDP

Humate-P Storage at room temperature

Special Access Programs (Health Canada)

2009-02

2009-02-15

Important Information Regarding IVIG-Associated Hemolysis

2009-05

2009-02-05

Updated Information Regarding the Availability of octaplex®

2009-04

2009-01-15

Availability of Vivaglobin® (Immune Globulin Subcutaneous [Human])
Immune Globulin Comparison Table

Vivaglobin® available in January 2009 for Primary Immunodeficient patients throughout Canada

2009-03

2009-01-09

Launch of PrivigenTM A new liquid, 10%, IVIG product>
CSL Behring plans to launch a new 10% IVIG in January 2009: Privigentm

/\ Top

2008


Letter #

Date

Title

2008-29

2008-01-09

Important Information Regarding Double Platelet Collections – Follow-up

2008-28

2008-11-17

Important Information Regarding ISBT 128 Sample Labels and Product Codes
Attachments:
1, 2-1, 2-2, 2-3, 2-4, 2-5,
2-6, 2-7, 2-8, 2-9

2008-27

2008-10-15

Introduction of Privigentm
A new liquid, 10%, IVIG product
IVIG Comparison Table 2009-09-24
CSL Behring plans to launch Privigentm

2008-23

2008-10-14

Discontinuing Distribution of Infusion Sets

2008-25

2008-09-26

Important information regarding double platelet collections

2008-24

2008-09-23

Availability of Synagis® (Palivizumab) 2008-2009

2008-26

2008-09-15

CORRECTION: Introduction of wilate® (Human coagulation factor VIII and human von Willebrand factor)
Wilate Letter

2008-09

2008-08-11

Important Information Regarding a New Guideline for Investigation of Suspected Transfusion Transmitted Bacterial Contamination Available from the Public Health Agency of Canada

2008-22

2008-07-31

Important Information Regarding the Availability of octaplex®

2008-17

2008-07-24

Whole Blood Component Codes/Names Updates for the Buffy Coat Production Method

2008-21

2008-07-24

Changes to Recombinant Factor VIII & IX Products Distributed by Canadian Blood Services
Baxter Letter
Bayer Letter
Wyeth Letter

2008-19

2008-07-21

Important information regarding reduction of SAGM red blood cell minimum volume cut-off

2008-20

2008-07-17

Changes to Products Distributed by Canadian Blood Services:
1. Gamunex®/IGIVnex™ - Latex-free stoppers
2. Alburex® 5 – Availability of 500 mL vial size
Talecris Letter

2008-18

2008-06-20

Further Information Regarding Pre-1986/Post-1990 Hepatitis C Settlement Program
Refer to customer letter 2008-02

2008-07

2008-06-02

Important Information Regarding Circulars of Information: CBS to Begin using West Nile Virus (WNV)Nucleic Acid Testing (NAT) Licensed Test Kits

2008-16

2008-05-15

Changes to Products Distributed by Canadian Blood Services:
1. Advate® - Ancillary kit improvements
2. Berinert® P - Storage at room temperature & Administration kit
3. WinRho® SDF - New liquid formulation
Baxter Letter
CSL Behring Letter
Cangene Letter

2008-15

2008-05-07

Important Information Regarding Availbility of IVIG Products for 2008-2009

2008-12

2008-05-06

Important Information Regarding New Equipment for Apheresis Platelet Collections

2008-14

2008-04-21

Important Information Regarding: Availability of Health Canada Licensed CytoGam®
CSL Behring Letter
Products Table

2008-13

2008-04-15

Introduction of wilate® (Human coagulation factor VIII and human von Willebrand factor)
Octapharma Letter
Products Comparison Table

2008-06

2008-04-09

Important Information Regarding ISBT 128 Planned Implementation at Canadian Blood Services

2008-11

2008-04-09

Introduction of octaplex® (Human Prothrombin Complex)
Octapharma Letter

2008-03

2008-04-07

Important Information Regarding Revisions to Blood Component and Blood Product Order Forms

2008-10

2008-03-27

Health Canada's Special Access Programme (SAP): New Request Forms

2008-08

2008-03-06

Recombinant Factor VIII Products Distributed by Canadian Blood Services

2008-02

2008-02-14

Important Information Regarding Pre-1986/Post-1990 Hepatitis C Settlement Program

2008-05

2008-02-06

Further Information Regarding Primary TRALI Reduction Measures

2008-04

2008-01-25

New Recall Manual - Hospital Follow-Up Customer Letter
Notification Form

2008-01

2008-01-04

Important Information Regarding TRALI Laboratory Investigations
TRALI Info Form
For the latest version of this form, please go to www.transfusionmedicine.ca

/\ Top

2007

Letter # Date Title
2007-46 2007-12-17 Important Information Regarding: Completion of Recombinate Phase-out in Canada
Baxter Letter
2007-11 2007-12-14 Manual Transformation Product Label
2007-01 2007-11-29 Important Information Regarding Notification of Component Recall/Withdrawal Form
2007-45 2007-11-28 Important Information Regarding Medical Director London Centre, Canadian Blood Services
2007-44 2007-11-28 Important Information Regarding CPDA-1 Divided Products
2007-34 2007-11-23 Important Information Regarding Platelets Apheresis, LR Product Update
2007-30 2007-11-23 Important Information Regarding the Release of the 2004 and 2005 Circulars of Information - Amendments for the new Platelets Apheresis, LR Transfusion Instructions Label
2007-43 2007-11-14 CORRECTION: Introduction of Voluven®
Fresenius Kabi Pre-Letter
Fresenius Kabi Letter re:Voluven®
2007-38 2007-10-30 Important Information Regarding BeneFIX®
Wyeth Letter
2007-39 2007-10-29 Introduction of HepaGam BTM (Hepatitis B Immune Globulin (Human) Injection)
HepaGam B Launch Package
HBIg Comparison Table
2007-42 2007-10-23 Update on Canadian Blood Services' Organizational Structure
2007-41 2007-10-23 Update on Canadian Blood Services' Organizational Structure
2007-40 2007-10-23 Update on Canadian Blood Services' Organizational Structure
2007-37 2007-10-11 Important Information Regarding Humate P ®
Humate P Letter
2007-36 2007-10-10 Important Information Regarding Advate®
Notification of Advate® Packaging Changes
2007-35 2007-09-27 Update on Canadian Blood Services Inventory Levels
2007-33 2007-09-27 Availability of Synagis® (Palivizumab)
Request Form
2007-32 2007-09-19 Introduction of Voluven®
Fresenius Kabi Canada Letter - Deleted
See Customer Letter #2007-43 for further details

Comparison Table
2007-29 2007-08-23 Update on Canadian Blood Services Inventory Levels
2007-28 2007-08-23 Update on CytoGam® Distribution via the Special Access Programme (SAP)
CytoGam® Update
2007-24 2007-08-14 ISBT 128 Implementation at Héma-Québec
2007-27 2007-08-13 Important Information Regarding Current Canadian Blood Services Inventory Levels
2007-19 2007-08-10 Important Information Regarding Availability of IVIG Products for 2007-2008
Clinician GGL Notification Letter
IVIG Comparison Table
2007-15 2007-08-07 2005 Circular of Information for the Use of Human Blood and Blood Components - Booklet format for Buffy Coat Production Method
2007-25 2007-08-02 Important Information Regarding Primary TRALI Reduction Measures
2007-26 2007-07-27 Field Correction: Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized Humate-P
2007-18 2007-07-24 Important Information Regarding Change to ACD Fresh Frozen Plasma Apheresis Storage Bag
2007-23 2007-06-20 Important Information Regarding: Limited Availability of Albumin 25%
2007-21 2007-06-15 Important Information Regarding CytoGam® Requiring Temporary Special Access Programme (SAP) Authorization
Letter from CSL Behring Canada
Revised Special Access Programme (SAP) Products Table
2007-16 2007-05-08 Important Information Regarding Recombinate Antihemophilic Factor (Recombinant) (rAHF) Phase-out in Canada
Baxter Letter
2007-14 2007-04-24 Important Information Regarding Infusion Rate Inconsistencies Found in the CytoGam® Product Monograph
CSL Behring Letter - CytoGam
2007-13 2007-04-23 Introduction of New Pall Medical Red Cell Storage Bags
Questionnaire
2007-12 2007-04-04 Corporate Name Change - CSL Behring Canada, Inc. and Revised Special Access Programme (SAP) Products Table
CSL Behring Letter
Special Access Programme
2007-03 2007-02-27 Further Reducing the Risk of Bacterial Contamination of Platelet Concentrates
Reference Material 1
Reference Material 2
2007-09 2007-02-26 Important Information Regarding Availability of VariZIGTM [Varicella Zoster Immune Globulin (Human) Lyophilized and its Reconstitution
2007-08 2007-02-19 Revisions to the Plasma Proteins Order Form
Sample: Plasma protein order form
2007-10 2007-02-16 Revised Donation and Pool Number Labels
2007-05 2007-02-12 Changes to Blood Component Storage Containers
2007-07 2007-02-08 Implementation of a NewInventory Management System for Plasma Protein Products
2007-04 2007-02-01 ISBT 128 Implementation
2007-06 2007-01-26 Important Information Regarding Intravenous Immune Globulin (IVIG): Demand & Supply Trends and Utilization Guidelines
2007-02 2007-01-08 Bacterial Detection Testing

/\ Top

2006

Letter # Date Title
2006-35 2006-12-20 Expiry Date Extension - Fibrogammin P, Human Plasma Coagulation Factor XIII

Behring Letter
2006-29 2006-11-27 Calculation of the Check Digit - Donation Number Label and Pooled Number Label
2006-32 2006-10-20 Important Information Regarding: Limited Availability of Albumin 5%
2006-25 2006-10-05 Important Information Regarding the Availability of the 4th Edition of the "Clinical Guide to Transfusion"
2006-30 2006-10-02 Availability of Advate
2006-28 2006-09-29 Availability of Anti-RSV Immune Globulin

Respiratory Syncytial Virus Prophylaxis Request Form
2006-27 2006-09-20 Important Information Regarding IGIVnex and Gamunex

Talecris Letter
2006-22 2006-09-01 Revised Donation and Pool Number Labels
2006-09 2006-08-25 Component Name and Code - Fresh Frozen Plasma Apheresis
2006-26 2006-08-03 Introduction of Advate and phase-out of Recombinate Antihemophilic Factor:

Baxter Notification PDF 1.2 Mb

Advate fact sheet PDF 507 Kb
2006-05 2006-07-13 Update on Buffy Coat - Revised Implementation Plan and New Spiking Method
2006-17 2006-06-26 WinRhoR SDF Dosing Guidelines for Treatment of Immune Thrombocytopenic Purpura (ITP)

Cangene Letter
2006-21 2006-06-21 Room Temperature Storage Requirements for KogenateR FS Supplied with BIO-SET

Bayer Letter - Important Information
2006-16 2006-06-14 Blood Components and Blood Products Order Forms
2006-20 2006-06-12 Availability of IGIVnexTM (Immune Globulin Intravenous [Human] 10%) Talecris Letter
Talecris Information Insert
2006-24 2006-06-07 Availability of IVIG Products for 2006-2007
2006-19 2006-05-26 Corporate Changes - Talecris Biotherapeutics
2006-18 2006-05-09 Introduction of IGIVnexTM (Immune Globulin Intravenous [Human] 10%)
2006-04-28 IGIVnexTM and Mixing of Different Immune Globulin Intravenous (Human) Products, (Talecris)
2006-04-20 Talecris Letter to Doctors: Introducing IGIVnexTM, (Talecris)
2006-04-20 IGIVnexTM Fact Sheet: The Gamunex process with Canadian-donor plasma, (Talecris)
2006-01 2006-03-02 Important Information Regarding Hemofil M, Antihemophilic Factor (Human)(AHF), Method M, Monoclonal Purified
2006-01 2006-03-01 Removal of Hemofil M, plasma derived FVIII
2006-15 2006-02-17 Introduction of VariZIGTM (Varicella Zoster Globulin (Human)) Lyophilized (Powder for Injection) Formulation with Sterile Diluent
2006-08 2006-02-16 Hematocrit of SAGM Red Blood Cells, LR - Update from Edmonton Pilot
2006-15
Cangene
2006-02-15 Important Information – New Product Introduction, VariZIGTM (Varicella Zoster Immune Globulin (Human)) Lyophilized (Powder for Injection) Formulation with Sterile Diluent
2006-14 2006-02-09 Important Safety Information Regarding NiaStase® eptacog alfa (activated)
2006-14
Novo Nordisk
2006-02-08 Re: NiaStase® – U.S. Dear Healthcare Professional Letter
2006-14
FDA Letter
2005-11-23 Important Drug Warning
2006-13 2006-01-30 Important Safety Information Regarding WinRho® SDF ((Rho (D) Immune Globulin (Human))
2006-13
Cangene
2006-01-24 Health Canada Endorsed Important Safety Information on WinRho® SDF (Rho (D) Immune Globulin (Human))
2006-04 2006-01-12 Hospital Pandemic Planning Questionnaire
2006-03 2006-01-11 Baxter Products - Changes to the Lot Numbering Format
2006-03
Baxter
2006-01-04 RE: Changes to the Lot Numbering Format of Baxter Products

/\ Top

2005

Letter # Date Title
2005-42 2005-12-08 BIOLOGIC RECALL, URGENT – WinRho® SDF, Rh(D) Immune Globulin (Human) for Injection, 5,000 IU (1,000 µg) Lot #02404013 and #02404022
2005-42
Cangene
2005-12-08 Cangene Corporation issues BIOLOGIC RECALL
2005-42
Recall Lot #02404013
2005-12-08 Fractionated product recall/withdrawal customer reconciliation report
2005-42
Recall Lot #02404022
2005-12-08 Fractionated product recall/withdrawal customer reconciliation report
2005-40 2005-12-07 Expiry Date Extension – Fibrogammin® P, Human Plasma Coagulation Factor XIII
2005-40
ZLB Behring
2005-10-28 Fibrogammin® P, extended expiry date
2005-38 2005-11-25 Updated Plasma Product Manufacturer Contact Information
2005-33 2005-10-27 Introduction of BIO-SET Needle-less Reconstitution Set for Bayer Kogenate® FS (Antihemophilic Factor (Recombinant)) Formulated with Sucrose and Recommendation for Use of a Separate Injection Filter
2005-33
Bayer
2005-10-26 Introducing Kogenate® FS (Antihemophilic Factor (Recombinant)), Formulated with Sucrose, Supplied with BIO-SET Needle-less Reconstitution Set
2005-34 2005-10-21 Buffy Coat Production Method – Additional Product Testing Information
2005-31 2005-10-19 Important Information about GamunexTM Immune Globulin Intravenous (Human)
2005-31
(Talecris)
2005-10-19 Health Canada Endorsed Important Safety Information on Gamunex®
2005-32 2005-10-18 Corporate Name Change – ZLB Behring Canada Inc.
2005-35 2005-10-06 Availability of Anti-RSV Immune Globulin
2005-30 2005-09-27 Additional Information Pertaining to the Buffy Coat Production Method
2005-27 2005-09-12 Washed red blood cells during Buffy Coat Pilot
2005-20 2005-09-13 Important Information Regarding Buffy Coat Production Method – Circular of Information
2005-29 2005-08-25 Important Information Regarding the Availability of the 2004 Circular of Information for the Use of Human Blood and Blood Components
2005-28 2005-07-29 Ratification of the Agreement with Ontario Support Staff
2005-24 2005-08-02 Canadian Blood Services Plasma Products and Services
2005-26 2005-07-27 Update on Tentative Agreement Reached with Ontario Support Staff
2005-25 2005-07-18 Labour Disruption Averted – Tentative Agreement Reached with Support Staff/Union
2005-23 2005-07-11 Further Information Regarding Possible Labour Disruptions
2005-22 2005-07-08 Information Regarding Possible Labour Disruptions
2005-21 2005-07-08 Information Regarding Adverse Reaction (London Centre)
2005-19 2005-06-20 Recombinate – Changes to Lot Numbering Format
2005-03 2005-05-26 Buffy Coat Production Method
2005-18 2005-05-17 Planned Measures to Protect the Blood Supply from West Nile Virus (WNV) – 2005 Season
2005-15 2005-05-04 Important Information Regarding WinRho® SDF
2005-13 2005-03-30 Introduction of Donor Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc)
2005-14 2005-03-22 CORRECTION: Important Information Regarding Fibrinogen Concentrate
Special Access Programme (Health Canada): Table (2006-06-12)
2005-12 2005-03-21 Important Information Regarding Fibrinogen Concentrate
2005-10 2005-03-11 New Donation Number Label
2005-07 2005-03-14 Additional Component Names and Codes – Buffy Coat Production Method (Winnipeg)
2005-08 2005-03-07 ABO/Rh Labelling of Red Blood Cell Components
2005-04 2005-01-27 Component Names and Codes – Buffy Coat Production Method
2005-05
Table
2005-01-19 Updated Special Access Programme Table
2005-05 2005-01-19 Updated Special Access Programme
2005-01 2005-01-19 Important Information Regarding BeneFIX®
2005-06 2005-01-14 Canadian Blood Services Launches Transfusion Medicine Web Site
2005-02 2005-01-11 Important Information Regarding WinRho® SDF

/\ Top

2004

Letter # Date Title
2004-22 2004-12-08 Malaria Deferral - Dominican Republic
2004-21 2004-12-16 Health Canada Licensure of Humate-P
2004-20 2004-12-07 Kogenate FS with bar code labels
2004-17 2004-09-24 Availability of Anti-RSV Immune Globulins
2004-16 2004-08-05 CORRECTION: Update to Expiry Date Labelling on Plasma Protein Products
2004-13 2004-07-30 Update to Expiry Date Labelling on Plasma Protein Products
2004-15 2004-07-14 Manufacturing of Antihemophilic Factor (Porcine) - Hyate: C - Discontinued
2004-14 2004-07-08 Fast Facts - West Nile Virus and the Blood System
2004-12 2004-06-16 Bacterial Detection in Platelets Apheresis
2004-11
Table
2004-06-14 Special Access Programme (SAP) Table
2004-11 2004-06-14 Special Access Programme (Health Canada)
2004-03 2004-05-17 Canadian Blood Services to Begin Using HCV RNA and HIV-1 RNA Licensed Test Kits
2004-10 2004-04-30 Gammagard S/D - Changes to Lot Numbering Format
2004-09 2004-04-22 Information for Health Care Professionals with Respect to Plans to Further Protect the Blood Supply from West Nile Virus
2004-08 2004-04-29 Availability of IVIG Products for 2004-2005
2004-07 2004-04-15 Information Regarding Special Access Programme
2004-06 2004-03-12 Changes to Fractionated Product Recall/Withdrawal Procedure
2004-05 2004-02-25 Factor VII Concentrate TIM 4 Immuno - Labelled Potency Change
2004-02 2004-02-24 Minimizing the Risk of Bacterial Contamination of Cellular Blood Components
2004-04 2004-02-13 Recombinate, Antihemophilic Factor (Recombinant) (rAHF) - Changes to Diluent
2004-01 2004-01-12 Availability of GamunexTM (Immune Globulin Intravenous (Human))

/\ Top

2003

Letter # Date Title
2003-30 2003-12-11 Introduction of GamunexTM (Immune Globulin Intravenous (Human))
2003-28 2003-11-10 Supplemental Information
2003-27 2003-11-06 Recall of Sterile Water for Injection, U.S.P. Packaged with Humate®-P, (Antihemophilic Factor/von Willebrand Factor Complex (Human))
2003-26 2003-11-05

Quarantine of Humate®-P, (Antihemophilic Factor/von Willebrand Factor Complex (Human))

/\ Top


Top of the page Access to Information & Privacy Policies | Terms of Use | Copyright © 1998-2014 Canadian Blood Services. All rights reserved.